Mary Hames is a seasoned Medical Affairs executive with a proven track record of leading high-performing teams and delivering strategic impact across rare disease, diagnostics, and oncology. With a foundation in biochemical genetics and over a decade of industry experience, she has played pivotal roles in clinical operations, launch preparedness, and cross-functional leadership. Known for her ability to navigate complex medical landscapes, Mary has successfully built and led medical teams, advanced companion diagnostics, and driven field strategy across multiple therapeutic areas. Her leadership is marked by scientific rigor, operational excellence, and a deep commitment to improving outcomes for patients with rare and life-threatening conditions.

I am excited to share my executive biography, highlighting my journey in oncology, clinical research, and medical affairs over the past 25 years. From my work as a medical science liaison to my leadership in pharmacy education and healthcare consulting, I have been committed to advancing patient care, scientific innovation, and medical education. If you're interested in learning more about my background, expertise, and contributions to pharmaceutical sciences and healthcare strategy.

I am excited to share my executive biography, which highlights my journey in medical affairs, pharma sales, and scientific exchange. With over 22 years of experience leading high-performing teams, optimizing strategic execution, and driving AI-enabled learning, I am passionate about advancing patient outcomes and fostering innovation in healthcare. I am currently seeking board opportunities to expand my influence and contribute my expertise beyond my current space.

Matthew Smollin, PharmD, is an accomplished leader in medical affairs and clinical innovation with over 15 years of clinical experience and a decade of industry expertise spanning clinical research, regulatory strategy, and team leadership. As Vice President of Medical Affairs at Karius, Inc., he directs medical and scientific strategies, guiding breakthrough advancements in molecular diagnostics while navigating complex FDA and Medicare regulatory processes. Throughout his career, he has successfully built and managed high-performing teams, fostered strong relationships with key opinion leaders, and played a pivotal role in clinical trial design, publication strategy, and scientific engagement. A respected speaker and thought leader, Dr. Smollin’s expertise in infectious disease diagnostics and next-generation sequencing has shaped industry best practices and advanced clinical innovation. His dedication to scientific excellence, strategic vision, and ability to translate complex medical insights into impactful solutions make him a driving force in the evolution of precision medicine and diagnostic technologies.